Introduction: Numerous studies have reported alterations in the composition of gut microbiota in patients with acute ischemic stroke (AIS), with changes becoming more pronounced as the disease progresses. However, the association between the progression of transient ischemic attack (TIA) and AIS remains unclear. This study aims to elucidate the microbial differences among TIA, AIS, and healthy controls (HC) while exploring the associations between disease progression and gut microbiota.
Methods: Fecal samples were collected from acute TIA patients ( = 28), AIS patients ( = 235), and healthy controls ( = 75) and analyzed using 16 s rRNA gene sequencing. We determined characteristic microbiota through linear discriminant analysis effect size and used the receiver operating characteristic (ROC) curve to assess their predictive value as diagnostic biomarkers.
Results: Our results showed significant gut microbial differences among the TIA, AIS, and HC groups. Patients with AIS exhibited higher abundances of and along with lower abundances of and _UCG-004. Further analysis revealed that the abundance of characteristic bacteria, such as and , was negatively correlated with HDL levels, while was positively correlated with risk factors such as homocysteine (Hcy). In contrast, the abundance of _UCG-004 was negatively correlated with both Hcy and D-dimer levels. ROC models based on the characteristic bacteria and effectively distinguished TIA from AIS, yielding areas under the curve of 0.699 and 0.626, respectively.
Conclusion: We identified distinct changes in gut bacteria associated with the progression from TIA to AIS and highlighted specific characteristic bacteria as predictive biomarkers. Overall, our findings may promote the development of microbiome-oriented diagnostic methods for the early detection of AIS.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11582031 | PMC |
http://dx.doi.org/10.3389/fnagi.2024.1451968 | DOI Listing |
J Stroke Cerebrovasc Dis
January 2025
Department of Radiology, Mayo Clinic, Rochester, MN, USA. Electronic address:
Background: Patients with acute ischemic stroke (AIS) in the setting of atrial fibrillation (Afib) will need to start/resume anticoagulation (AC) as it is the mainstay for secondary stroke prevention. Several studies have compared the safety and outcomes of starting/resuming AC in early or late start windows (ESW or LSW) but there is no consensus in clinical practice on the optimal timing of anticoagulation. This meta-analysis aims to compare the safety and outcome measures after resuming AC in the ESW versus LSW in patients with Afib after AIS.
View Article and Find Full Text PDFEur J Neurol
January 2025
Department of Clinical Medicine, Danish Centre for Health Services Research, Aalborg University, Aalborg, Denmark.
Background And Purpose: Emerging evidence indicates lasting impairments in patients with transient ischaemic attack (TIA), which may be unexpected as symptoms per definition recover within 24 h. How these impairments impact return to work or the ability to maintain independence is unknown. The aim of our study was to investigate the need of sick leave or homecare following TIA compared with acute ischaemic stroke (AIS).
View Article and Find Full Text PDFFront Aging Neurosci
November 2024
Department of Geriatrics, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Introduction: Numerous studies have reported alterations in the composition of gut microbiota in patients with acute ischemic stroke (AIS), with changes becoming more pronounced as the disease progresses. However, the association between the progression of transient ischemic attack (TIA) and AIS remains unclear. This study aims to elucidate the microbial differences among TIA, AIS, and healthy controls (HC) while exploring the associations between disease progression and gut microbiota.
View Article and Find Full Text PDFNeurologist
November 2024
Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao, China.
CNS Drugs
January 2025
Neurology Department, Faculty of Medicine, Kafr el-sheikh University, Elgeish Street, Kafr el-sheikh, Egypt.
Background: Many studies evaluated the efficacy and safety of ticagrelor versus clopidogrel in patients with ischemic stroke; none of these trials included North African participants, and all of these trials comprised only participants who experienced transient ischemic attack (TIA) or minor stroke.
Objectives: We compared the efficacy and safety of ticagrelor versus clopidogrel in patients with first-ever noncardioembolic moderate or moderate-to-severe ischemic stroke.
Methods: Our trial involved 900 first-ever noncardioembolic patients with acute ischemic stroke (AIS) who randomly received either loading and maintenance doses of ticagrelor or clopidogrel within the first 24 h of stroke onset.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!